Keywords

• Olaparib
• AZD2281
• KU0059436

Quick Details

• ProName: Olaparib
• CasNo: 763113-22-0
• Molecular Formula: C24H23FN4O3
• Appearance: white powder
• Application: For laboratory use only- not intended ...
• ProductionCapacity: 1 Kilogram/Month
• Purity: ≥99%
• Storage: room temperature
• Transportation: by air
• LimitNum: 10 Gram

Superiority

Details

Olaparib is a potent PARP inhibitor with IC₅₀ of 5 and 1 nM for PARP-1 and PARP-2, respectively. IC50 & Target: IC50: 5/1 nM (PARP-1/2).  In Vitro: Olaparib (AZD2281) is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Olaparib is applied to SW620 cell lysates, and identified the IC₅₀ for PARP-1 inhibition to be around 6 nM and the total ablation of PARP-1 activity to be at concentrations of 30 100 nM. In Vivo: Animals bearing SW620 xenografted tumors are treated with Olaparib (10 mg/kg, p.o.) in combination with Temozolomide (TMZ) (50 mg/kg, p.o.) once daily for 5 consecutive days, after which the tumors are left to grow out. Olaparib increases vascular perfusion in Calu-6 tumors established in a DWC model. Administration of olaparib(50 mg/kg, p.o.) as a single agent (top panel) or in combination with radiation (bottom panel) results in an increase in fluorescence intensity in the Calu-6 tumors.